Low Risk Myelodysplastic Syndromes
3
1
2
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Rvu120 Sel120
Research Leaders
11 sponsors active, led by Hospital Universitario Central de Asturias
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (3)
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS
Research Network
Common Treatments
- Rvu120 Sel1201
- R906289 Monosodium R289 Na1
Active Sponsors
- Hospital Universitario Central de Asturias1
- Fundación para la Investigación Biosanitaria del Principado de Asturias1
- Saint-Louis Hospital, Paris, France1
- Universitätsklinikum Leipzig1
- University of Salamanca1
Top Investigators
Universitätsklinikum Leipzig
Service d'hématologie seniors Hôpital Saint-Louis, Paris
University of Careggi, Italy
Medical University of Warsaw
University of Salamanca
Related Conditions
- Anemia In Patients With Very Low Low Or Intermediate Risk Myelodysplastic Neoplasms Mds1